Professional Documents
Culture Documents
Effects of Conjugated Equine Estrogen On Health-Related Quality of Life in Postmenopausal Women With Hysterectomy
Effects of Conjugated Equine Estrogen On Health-Related Quality of Life in Postmenopausal Women With Hysterectomy
Background: The Women’s Health Initiative (WHI) benefit, 0.4 points on a 20-point scale) and a statisti-
clinical trial of conjugated equine estrogens (CEEs), in- cally significant but small negative effect on social
volving 10 739 postmenopausal women with hysterec- functioning (mean effect, −1.3 points on a 100-point
tomy, aged 50 to 79 years, was stopped early owing to scale). There were no significant improvements due to
lack of overall health benefit and increased risk of stroke. CEE in the areas of general health, physical function-
Because CEE is still prescribed for treatment of meno- ing, pain, vitality, role functioning, mental health,
pausal symptoms and prevention of osteoporosis, it is im- depressive symptoms, cognitive function, or sexual
portant to understand the overall impact of this therapy satisfaction at year 1. A subgroup examined 3 years
on health-related quality of life (HRQOL). after baseline had no significant benefits for any
HRQOL outcomes. Among women aged 50 to 54 years
Methods: All participants completed 6 specific mea- with moderate to severe vasomotor symptoms at base-
sures of quality of life at baseline and 1 year, and a sub- line, CEE did not improve any of the HRQOL vari-
sample (n=1189) also completed the questions 3 years ables at year 1.
after randomization. Changes in scores were analyzed for
treatment effect. Conclusion: In this trial of postmenopausal women
with prior hysterectomy, oral CEE did not have a
Results: Randomization to CEE was associated with a clinically meaningful effect on HRQOL.
statistically significant but small reduction in sleep
disturbance at year 1 compared with baseline (mean Arch Intern Med. 2005;165:1976-1986
R
ESULTS OF RECENTLY PUB- that active treatment produced relief from
lished large, randomized vasomotor symptoms, the health-related
clinical trials have failed to quality of life (HRQOL) effects were lim-
support protective effects of ited to modest changes in physical func-
oral estrogen therapy alone tioning, sleep disturbance, and bodily pain
or estrogen plus progestin therapy on car- that were considered too small to be of
diovascular disease when administered to clinical significance on a population
postmenopausal women.1-3 Findings of the basis.5-7
Women’s Health Initiative (WHI)4 dem- The origin of the HRQOL concept has
onstrated that, compared with placebo, often been attributed to the World Health
women taking conjugated equine estro- Organization position that health is a “state
gens (CEEs) were at increased risk for of complete physical, mental and social
stroke and deep vein thrombosis and at de- well-being and not merely the absence of
creased risk for osteoporotic fractures. The infirmity and disease.”8 Health-related
global risk-benefit profile was neutral in quality of life (QOL) limits the influ-
the CEE treatment group, and the planned ences on QOL to medical conditions
Author Affiliations are listed at 8.5-year randomized clinical trial (RCT) and/or their treatment.9
the end of this article.
was stopped after an average of 6.8 years Typical self-assessment of HRQOL ex-
Group Information: A complete
list of investigators in the of follow-up (range, 5.7-10.7 years). amines aspects of functioning that may re-
Women’s Health Initiative Although the parallel WHI trial of late to disease symptoms, disability, and
appears in the box on pages CEE and medroxyprogesterone acetate outcome.10 Many HRQOL instruments tar-
1984 and 1985. (CEE ⫹ MPA) and other results showed get symptoms for specific medical condi-
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1976
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1977
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1978
Placebo P
Characteristic CEE Group Group Value
Age at screening, y
50-54 687 (12.9) 709 (13.1)
55-59 950 (17.9) 964 (17.8)
.94
60-69 2387 (45.0) 2465 (45.4)
70-79 1286 (24.2) 1291 (23.8)
Ethnicity
White 4007 (75.5) 4075 (75.1)
Black 782 (14.7) 835 (15.4)
Hispanic 322 (6.1) 333 (6.1)
.81
American Indian 41 (0.8) 34 (0.6)
Asian/Pacific Islander 86 (1.6) 78 (1.4)
Unknown 72 (1.4) 74 (1.4)
BMI (collapsed categories)
⬍25 1110 (21.0) 1096 (20.3)
25-⬍30 1795 (34.0) 1912 (35.5) .26
ⱖ30 2376 (45.0) 2383 (44.2)
Education
0-8 y 181 (3.4) 148 (2.7)
Some high school 354 (6.7) 370 (6.9)
High school diploma/GED 1233 (23.5) 1188 (22.1) .06
School after high school 2271 (43.2) 2350 (43.7)
College degree or higher 1216 (23.1) 1327 (24.7)
Annual family income, $
⬍10 000 423 (8.4) 441 (8.6)
10 000-19 999 999 (19.9) 990 (19.4)
20 000-34 999 1492 (29.8) 1507 (29.5)
.90
35 000-49 999 947 (18.9) 1000 (19.6)
50 000-74 999 725 (14.5) 722 (14.1)
ⱖ75 000 422 (8.4) 444 (8.7)
Age at hysterectomy, y
⬍40 2100 (39.8) 2149 (39.8)
40-49 2281 (43.2) 2275 (42.2)
.34
50-54 501 (9.5) 566 (10.5)
ⱖ55 401 (7.6) 404 (7.5)
Years since menopause
⬍5 330 (7.3) 325 (7.0)
5 to ⬍10 496 (11.0) 492 (10.6)
.83
10 to ⬍15 704 (15.7) 734 (15.8)
ⱖ15 2963 (65.9) 3085 (66.5)
Duration of previous hormone use, y
0 2769 (52.1) 2770 (51.0)
⬍5 1352 (25.5) 1412 (26.0)
.53
5 to ⬍10 469 (8.8) 515 (9.5)
ⱖ10 720 (13.6) 732 (13.5)
Baseline moderate/severe vasomotor symptoms
No 4327 (82.6) 4431 (82.9)
.71
Yes 913 (17.4) 917 (17.1)
History of CVD
No 4768 (90.9) 4893 (91.3)
.53
Yes 477 (9.1) 469 (8.7)
Prior bilateral oophorectomy
No 2973 (60.5) 2917 (58.0)
.01
Yes 1938 (39.5) 2111 (42.0)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CEE, conjugated equine estrogen;
CVD, cardiovascular disease; GED, General Educational Development test.
better or somewhat better health than participants in the not shown). In both groups, less than 3% reported poor
CEE group (23%) (Table 5). and 40% reported excellent global QOL. The CEE and pla-
The single global item asked: “Overall, how would you cebo groups were very similar in the proportions of par-
rate your quality of life?” The distributions of global scores ticipants who rated their global QOL in the moderate and
did not differ between the CEE and placebo groups (data good categories (26%-30%). Table 6 offers a sense of the
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1979
Abbreviations: CEE, conjugated equine estrogen; 3MSE, Modified Mini-Mental State Examination; QOL, quality of life.
*Scored from 0 (worst) to 100 (best).
†P value is statistically significant at Bonferroni corrected ␣ level of 0.005; in all tables actual, unadjusted P values are presented.
‡Scored from 4.0 (worst) to −8.1 (best).
§Scored from 0 (worst) to 20 (best).
||Scored from 0 (worst) to 4 (best).
metric for HRQOL (eg, RAND36 scores) by showing dif- sitivity analysis of our primary results. Adjustment of bi-
ferences that are associated with categorical increments in lateral oophorectomy status did not change conclusions
global QOL. As examples, the HRQOL mean scores were regarding sleep disturbance; the mean difference be-
approximately 1 SD higher for women who rated their global tween the CEE and placebo groups changed from 0.40
QOL as excellent compared with those who rated it as mod- to 0.38 and remained statistically significant (Pⱕ.001).
erate. The HRQOL sleep disturbance score was 3 points However, oophorectomy adjustment slightly attenu-
higher (less disturbance) for women rating their global QOL ated the effect of CEE on social functioning; after adjust-
as excellent compared with those who rated it as moder- ment, the mean difference changed from −1.31 to −1.16
ate. Higher ratings of global QOL were associated with (P=.01) and consequently did not reach the Bonferroni-
higher scores on each of the RAND36 subscales and lower corrected ␣ level. None of the other results were changed
scores on the depression measures, all suggesting that this after adjusting for bilateral oophorectomy status.
global item is sensitive to symptoms and functioning. Also,
regardless of treatment assignment, moderate to severe
COMMENT
menopausal symptoms and adverse effects of hormone
therapy were significantly associated with worse global QOL.
Because of the slight imbalance of bilateral oophorec- In the WHI RCT of CEE alone,4 a clinically meaningful
tomy status by treatment assignment, we performed a sen- benefit of CEE treatment on HRQOL was not found in
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1980
Abbreviations: CEE, conjugated equine estrogen; 3MSE, Modified Mini-Mental State Examination; QOL, quality of life.
*Scored from 0 (worst) to 100 (best).
†Scored from 4.0 (worst) to −8.1 (best).
‡Scored from 0 (worst) to 20 (best).
§Scored from 0 (worst) to 4 (best).
an ethnically diverse population of postmenopausal both trials, a statistically significant, small improve-
women who had undergone hysterectomy before enter- ment in average sleep disturbance score was found after
ing the study. Failure to demonstrate global improve- 1 year of hormone treatment. Women with vasomotor
ment in HRQOL occurred, despite absence of uterine symptoms experienced a significant decline in these symp-
bleeding or other progestin-associated adverse effects. toms, but the positive effects on physical functioning and
These results were similar to results reported for bodily pain seen in the WHI CEE⫹ MPA trial were not
women with a uterus in the WHI CEE⫹ MPA trial.5 In found here.
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1981
Several baseline differences in HRQOL were noted be- decide what they consider statistically significant. For ex-
tween women in the CEE⫹MPA trial (with a uterus) and ample, applying a liberal ␣ value of .05 would only add
women in the CEE trial (without a uterus). The average a statistically significant improvement in physical func-
bodily pain score at baseline was significantly more nega- tioning from CEE, which then is perhaps offset by a sig-
tive (more pain) in the CEE trial than in the CEE⫹MPA nificant negative change in cognitive functioning.
trial (Pⱕ.001). Similarly, women in the CEE trial had The minimal benefit of CEE on HRQOL (2% improve-
worse physical functioning scores at baseline (Pⱕ.001). ment in sleep disturbance symptoms) does not chal-
Also, in the CEE⫹MPA trial, at baseline, fewer women lenge the current treatment guidelines. The findings sug-
reported poor and more reported excellent global QOL gest that asymptomatic women using estrogen therapy,
than in the present trial (P⬍.001). However, after 1 year, eg, for prevention of osteoporosis, are unlikely in the short
the CEE and CEE⫹MPA groups did not differ from their term to experience a meaningful improvement in HRQOL.
respective placebo groups in global QOL. The sub- Overall, our results are consistent with other recent ran-
sample with HRQOL undergoing reassessment 3 years domized trials46,47 and epidemiological studies.48 The WHI
from baseline provided no evidence that longer-term use and other studies indicate that some menopausal vasomo-
of CEE improves HRQOL measures compared with a tor symptoms improve with estrogen treatment. There is
shorter-term use. It could be argued that the limited ef- little or no benefit of systemic hormone treatment for most
fects of CEE on HRQOL resulted from a too conserva- other physical, functional, and psychosocial conditions, with
tive ␣ level probability threshold, one that had been ad- some, like nocturnal urinary frequency, worsening.49,50 The
justed for multiple comparisons. However, we have HRQOL measures may be considered subjective aggre-
presented actual (unadjusted) P values, so the reader may gates that are complexly influenced by the combination of
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1982
Abbreviations: HRQOL, health-related QOL; 3MSE, Modified Mini-Mental State Examination; QOL, quality of life; RAND36, RAND 36-Item Health Survey.
*Includes myocardial infarction, hip fracture, invasive breast cancer, colon cancer, stroke, and pulmonary embolism before their year 1 QOL data were collected.
†P⬍.001 based on 1-sided Cochran-Armitage test for linear trend to test whether higher prevalence of symptoms and higher incidence of events are associated
with lower global QOL.
‡These symptoms were identified a priori and are based on the Women’s Health Initiative conjugated estrogen and medroxyprogesterone acetate gynecological
symptoms data).45
§Includes hot flashes and/or night sweats.
||These effects were identified a priori based on the Women’s Health Initiative conjugated estrogen and medroxyprogesterone acetate gynecological symptoms
data.45
¶P⬍.001 based on 1-sided test for linear trend to determine whether higher HRQOL scores are associated with higher global QOL scores.
estrogen replacement’s improvement in vasomotor symp- CEE ⫹ MPA trial in women without a hysterectomy.
toms (and/or other unspecified positive effects), adverse We attribute the latter difference largely to more health
effects, and consequences for disease processes and end risk factors and lower socioeconomic status in the
points. Part of the rationale for the original study design women with hysterectomy.
was that estrogen would have health benefits (bone, heart, Some reports suggest that estrogen therapy might play
and cognition) that would be reflected in HRQOL mea- a role in the management of severe emotional and mental
sures. The absence of an improvement with estrogen in changes in the postpartum or perimenopausal peri-
the global index, the study’s overall risk-benefit health ods.51,52 The impact of estrogen treatment in clinical mood
profile,4 may help explain the weak response of HRQOL disorders may be very different than its population effects
measures. in healthy women not selected for such disturbances.
As a randomized clinical trial of relatively healthy Estrogen therapy alone in women with a hysterec-
women after menopause, it might be argued that the po- tomy did not produce clinically meaningful improve-
tential for positive health differences was limited by a ments in HRQOL measures compared with placebo, de-
“ceiling” that effectively reduced the range of scores at spite reduction of some vasomotor symptoms resulting
the upper end of the spectrum. This may be the case for from the active treatment, albeit in the relatively small
the 2-item social functioning subscale (mean score proportion of women in the cohort who were symptom-
lower in the CEE group) of the RAND36, which has a atic. Any overall impact may have been lessened by the
coarse Likert scale. Most participants attained the maxi- size of the specific effect on sleep disturbance, which, as
mum score on social functioning. For other subscales, one of the more widely reported and enduring prob-
average scores were well below the possible maximum. lems in this age group, had only a small average improve-
For example, only 1% of subjects had maximum vitality ment, perhaps because nocturnal urinary frequency may
scores, and baseline HRQOL scores were generally worsen with hormone treatment.49 Moreover, recent re-
lower in this population than in the previously reported views have suggested that subjectively reported sleep dis-
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1983
Clinical Centers
Albert Einstein College of Medicine, Bronx, NY: Sylvia Wassertheil-Smoller, William Frishman, Judith Wylie-Rosett,
David Barad, and Ruth Freeman. Baylor College of Medicine, Houston, Tex: Jennifer Hays, Ronald Young, Jill Ander-
son, Sandy Lithgow, and Paul Bray. Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass: JoAnn
Manson, Julie Buring, Kathryn Rexrode, Claudia Chae, and Caren Solomon. Brown University, Providence, RI: Ann-
louise R. Assaf, Carol Wheeler, Charles Eaton, and Michelle Cyr. Emory University, Atlanta, Ga: Lawrence Phillips,
Margaret Pedersen, Ora Strickland, Margaret Huber, and Vivian Porter. Fred Hutchinson Cancer Research Center, Se-
attle, Wash: Shirley A. A. Beresford, Vicky M. Taylor, Nancy F. Woods, Maureen Henderson, and Robyn Andersen.
George Washington University, Washington, DC: Judith Hsia, Nancy Gaba, and Joao Ascensao. Harbor/University of
California–Los Angeles Research and Education Institute, Torrance: Rowan Chlebowski, Robert Detrano, Anita Nel-
son, and Michele Geller. Kaiser Permanente Center for Health Research, Portland, Ore: Evelyn Whitlock, Patricia Elmer,
Victor Stevens, and Njeri Karanja. Kaiser Permanente Division of Research, Oakland, Calif: Bette Caan, Stephen Sid-
ney, Geri Bailey and Jane Hirata. Medical College of Wisconsin, Milwaukee: Jane Morley Kotchen, Vanessa Barnabei,
Theodore A. Kotchen, Mary Ann C. Gilligan, and Joan Neuner. MedStar Research Institute/Howard University, Wash-
ington, DC: Barbara V. Howard, Lucile Adams-Campbell, Lawrence Lessin, Monique Rainford, and Gabriel Uwaifo.
Northwestern University, Chicago/Evanston, Ill: Linda Van Horn, Philip Greenland, Janardan Khandekar, Kiang Liu,
and Carol Rosenberg. Rush-Presbyterian St Luke’s Medical Center, Chicago: Henry Black, Lynda Powell, Ellen Mason,
and Martha Gulati. Stanford Center for Research in Disease Prevention, Stanford University, Stanford, Calif: Marcia L.
Stefanick, Mark A. Hlatky, Bertha Chen, Randall S. Stafford, and Linda C. Giudice. State University of New York at
Stony Brook: Dorothy Lane, Iris Granek, William Lawson, Gabriel San Roman, and Catherine Messina. The Ohio
State University, Columbus: Rebecca Jackson, Randall Harris, Electra Paskett, W. Jerry Mysiw, and Michael Blumen-
feld. University of Alabama at Birmingham: Cora E. Lewis, Albert Oberman, James M. Shikany, Monika Safford, and
Brian K. Britt. University of Arizona, Tucson/Phoenix: Tamsen Bassford, Cyndi Thomson, Marcia Ko, and Ana Maria
Lopez. University at Buffalo, Buffalo, NY: Jean Wactawski-Wende, Maurizio Trevisan, Ellen Smit, Susan Graham,
and June Chang. University of California at Davis, Sacramento: John Robbins and S. Yasmeen. University of California
at Irvine, Orange: Allan Hubbell, Gail Frank, Nathan Wong, Nancy Greep, and Bradley Monk. University of Califor-
nia at Los Angeles: Howard Judd, David Heber, and Robert Elashoff. University of California at San Diego, LaJolla/
Chula Vista: Robert D. Langer, Michael H. Criqui, Gregory T. Talavera, Cedric F. Garland, R. and Elaine Hanson.
University of Cincinnati, Cincinnati, Ohio: Margery Gass, Suzanne Wernke, and Nelson Watts. University of Florida,
Gainesville/Jacksonville: Marian Limacher, Michael Perri, Andrew Kaunitz, R. Stan Williams, and Yvonne Brinson.
University of Hawaii, Honolulu: David Curb, Helen Petrovitch, Beatriz Rodriguez, Kamal Masaki, and Santosh Sharma.
University of Iowa, Iowa City/Davenport: Robert Wallace, James Torner, Susan Johnson, Linda Snetselaar, and Jen-
nifer Robinson. University of Massachusetts/Fallon Clinic, Worcester: Judith Ockene, Milagros Rosal, Ira Ockene, Rob-
ert Yood, and Patricia Aronson. University of Medicine and Dentistry of New Jersey, Newark: Norman Lasser, Baljinder
Singh, Vera Lasser, and John Kostis. University of Miami, Miami, Fla: Mary Jo O’Sullivan, Linda Parker, R. Estape,
and Diann Fernandez. University of Minnesota, Minneapolis: Karen L, Margolis, Richard H. Grimm, Donald B. Hun-
ninghake, June LaValleur, and Sarah Kempainen. University of Nevada, Reno: Robert Brunner, Michael Bloch,William
Graettinger, and Vicki Oujevolk. University of North Carolina, Chapel Hill: Gerardo Heiss, Pamela Haines, David Ontjes,
Carla Sueta, and Ellen Wells. University of Pittsburgh, Pittsburgh, Pa: Lewis Kuller, Jane Cauley, and N. Carole Milas.
University of Tennessee, Memphis: Karen C. Johnson, Suzanne Satterfield, Raymond W. Ke, Stephanie Connelly, and
Fran Tylavsky. University of Texas Health Science Center, San Antonio: Robert Brzyski, Robert Schenken, Jose Trabal,
Mercedes Rodriguez-Sifuentes, and Charles Mouton. University of Wisconsin, Madison: Gloria Sarto, Douglas Laube,
Patrick McBride, Julie Mares-Perlman, and Barbara Loevinger. Wake Forest University School of Medicine, Winston-
Salem, NC: Denise Bonds, Greg Burke, Robin Crouse, Mara Vitolins, and Scott Washburn. Wayne State University
School of Medicine/Hutzel Hospital, Detroit, Mich: Susan Hendrix, Michael Simon, and Gene McNeeley.
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1984
turbance during and after menopause has multiple causes Role of the Sponsor: The National Heart, Lung, and Blood
and that its relationship to hormone changes is com- Institute funded the Women’s Health Initiative. Scien-
plex.53,54 In the WHI, health risks and benefits were rela- tists from the NIH participated in the design of the study
tively balanced after more than 6 years of CEE use. In- but did not participate in data collection or analysis and
dividual women may experience some improvement in are not among the authors of this article.
their vasomotor and urogenital atrophy symptoms, but
these may be partly offset by adverse effects associated
with postmenopausal hormone treatment. We find no evi- REFERENCES
dence of an HRQOL benefit for the general postmeno-
pausal population. 1. Grady D, Herrington D, Bittner V, et al; HERS Research Group. Cardiovascular
disease outcomes during 6.8 years of hormone therapy: heart and estrogen/
progestin replacement study follow-up (HERS II). JAMA. 2002;288:49-57.
Accepted for Publication: May 19, 2005. 2. Herrington DM, Reboussin DM, Klein KP, et al. The Estrogen Replacement and
Author Affiliations: Department of Family and Com- Atherosclerosis (ERA) Study: study design and baseline characteristics of the
munity Medicine, University of Nevada School of Medi- cohort [published correction appears in Control Clin Trials. 2000;21:414]. Con-
trol Clin Trials. 2000;21:257-285.
cine, Reno (Dr Brunner); Department of Obstetrics/ 3. WHI Writing Group. Risks and benefits of estrogen plus progestin in healthy post-
Gynecology, University of Cincinnati, Cincinnati, Ohio menopausal women. JAMA. 2002;288:321-333.
(Dr Gass); Clinical Coordinating Center, Fred Hutchin- 4. Anderson GL, Limacher M, Assaf AR, et al; Women’s Health Initiative Steering
son Cancer Research Center (Mr Aragaki and Dr LaCroix), Committee. Effects of conjugated equine estrogen in postmenopausal women
and University of Washington School of Nursing, Cen- with hysterectomy: the Women’s Health Initiative Randomized Controlled Trial.
JAMA. 2004;291:1701-1712.
ter for Women’s Health Research (Dr Woods), Seattle; 5. Hays J, Ockene JK, Brunner RL, et al; Valanis BG for the Women’s Health Initia-
Women’s Health Center, Department of Medicine, Bay- tive Investigators. Effects of estrogen plus progestin on health-related quality of
lor College of Medicine, Houston, Tex (Dr Hays); De- life: results from the Women’s Health Initiative Randomized Clinical Trial. N Engl
partment of Preventive Medicine, State University of New J Med. 2003;348:1839-1854.
6. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of
York at Stony Brook (Dr Granek); Department of Ob- postmenopausal hormones: results from the postmenopausal estrogen/
stetrics and Gynecology, John H. Stroger Jr Hospital of progestin interventions trial. Obstet Gynecol. 1998;92:982-988.
Cook County, Chicago, Ill (Dr Mason); Department Ob- 7. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women
stetrics and Gynecology, University of Texas Health Sci- and the effects of treatment with hormone therapy. Obstet Gynecol. 2002;100:
ence Center, San Antonio (Dr Brzyski); Division of Pre- 1209-1218.
8. World Health Organization. World Health Organization constitution. In: Basic Docu-
ventive and Behavioral Medicine, University of ments. Geneva, Switzerland: World Health Organization; 1948.
Massachusetts Medical School, Worcester (Dr Ockene); 9. Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology (Willis-
Department of Community Health, Brown University, ton Park). 1995;9(11 suppl):47-60.
Providence, RI (Dr Assaf); Department of Psychiatry, Uni- 10. Guyatt GH, Naylor D, Juniper E, Heyland DK, Jaeschke R, Cook DJ; Evidence-
Based Medicine Working Group. Users’ guide to the medical literature, XII: how
versity of Pittsburgh, Pittsburgh, Pa (Dr Matthews); and to use articles about health-related quality of life. JAMA. 1997;277:1232-1237.
Department of Epidemiology, University of Iowa, Iowa 11. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional
City (Dr Wallace). assessment of chronic illness therapy measurement system. Arch Phys Med
Correspondence: Robert L. Brunner, PhD, Department Rehabil. 2002;83:S10-S17.
of Family and Community Medicine, University of Ne- 12. Hunt SM. The problem of quality of life. Qual Life Res. 1997;6:205-212.
13. Dempster M, Donnelly M, Fitzsimons D. Generic, disease-specific and indi-
vada School of Medicine, MS145, Reno, NV 89557 vidualised approaches to measuring health-related quality of life among
(bbrunner@whi.org). people with heart disease: a comparative analysis. Psychol Health. 2002;17:
Financial Disclosure: Dr Assaf is an employee of Pfizer, 447-457.
which during part of the conduct of the study, made a 14. Alder EM. How to assess quality of life: problems and methodology. In: Schneider
HPG, ed. Hormone Replacement Therapy and Quality of Life. New York, NY: Par-
competing drug to conjugated estrogens (Premarin), the thenon Publishing Group Inc; 2002.
study drug made by Wyeth-Ayerst. Pfizer has since di- 15. Stansfeld SA, Roberts R, Foot SP. Assessing the validity of the SF-36 General
vested the company of the subsidiary that made the hor- Health Survey. Qual Life Res. 1997;6:217-224.
mone drug. 16. Rothert M, Padonu G, Holmes-Rovner M, et al. Menopausal women as decision
Funding/Support: The Women’s Health Initiative is makers in health care. Exp Gerontol. 1994;29:463-468.
17. Zethraeus N, Johannesson M, Henriksson P, Strand R. The impact of hormone
funded by the National Heart, Lung, and Blood Insti- replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol.
tute, US Department of Health and Human Services, Na- 1997;104:1191-1195.
tional Institutes of Health (NIH), Bethesda, Md. 18. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? meno-
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1985
(REPRINTED) ARCH INTERN MED/ VOL 165, SEP 26, 2005 WWW.ARCHINTERNMED.COM
1986